
Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target
Arrowhead Pharmaceuticals (ARWR) Analyst Ratings
Bulls say
Arrowhead Pharmaceuticals is supported by a validated TRiM RNAi platform that is now translating into both commercial traction and broader pipeline optionality, with Redemplo generating $6.6 million in FCS revenue, 860 unique prescribers, and weekly scripts rising to about 50-60 from 20-30 last quarter. The company’s upbeat thesis is reinforced by its sNDA submission on November 2nd for sHTG under the STAR program, which preserves a roughly $215 million Priority Review Voucher and could support a launch in 2H27, while management reiterates $3-4 billion peak sales potential and is already engaging 20,000 potential prescribers. Beyond APOC3, multiple programs are advancing on track with de-risking data in CNS, cardiometabolic, and liver assets, and the $825 million upfront Sarepta collaboration plus low-double-digit royalties strengthens runway into 2028 and highlights the franchise’s strategic value.
Bears say
Arrowhead Pharmaceuticals is facing a challenging fundamental setup because its latest quarter showed sharply elevated spending, with R&D at $190 million and G&A rising to $282 million, including the $215 million PRV purchase. That cost structure drove a net loss of $428 million, or $3.02 per share, far worse than the expected $1.58 loss, signaling weak operating leverage despite an end-of-quarter cash balance of $1.2 billion. Although Redemplo is now authorized in multiple major markets and the pipeline remains broad, the company still depends on costly clinical development across many programs, leaving execution and profitability risks high.
This aggregate rating is based on analysts' research of Arrowhead Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Arrowhead Pharmaceuticals (ARWR) Analyst Forecast & Price Prediction
Start investing in Arrowhead Pharmaceuticals (ARWR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Arrowhead Pharmaceuticals (ARWR) Forecast
Arrowhead Pharmaceuticals (ARWR) Analyst Forecast & Price Prediction
Start investing in Arrowhead Pharmaceuticals (ARWR)
Order type
Buy in
Order amount
Est. shares
0 shares